New drug IBI343 for advanced pancreatic cancer with CLDN18.2 protein
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new drug called IBI343 compared to a placebo (inactive substance) for people with advanced pancreatic cancer that has a specific protein (CLDN18.2) and has not responded to earlier treatments. The goal is to see if IBI343 can help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your pancreatic cancer is advanced (cannot be removed by surgery) or has spread to other parts of the body.
- You have already tried at least two different chemotherapy treatments, including one with fluorouracil and one with gemcitabine, and your cancer got worse during or after that treatment.
- Your tumor must test positive for a protein called CLDN18.2 (Claudin 18.2).
- You are generally able to care for yourself and are up and about more than half the day (ECOG score 0 or 2).
- Your blood counts and organ function (like liver and kidneys) are within a range that is safe for the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (IBI343) combined with chemotherapy given before surgery for pancreatic cancer that is borderline resectable. The goal is to shrink the tumor enough so it can be removed with surgery, and this treatment focuses on a specific marker on cancer cells.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.